- Home
- ST vs MIRM Comparison
ST vs MIRM Comparison
Compare ST & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ST | MIRM |
|---|---|---|
| Founded | 1916 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 7.2B |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ST | MIRM |
|---|---|---|
| Price | $42.60 | $80.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $53.30 | ★ $151.64 |
| AVG Volume (30 Days) | ★ 1.1M | 798.6K |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $3,704,500,000.00 | $19,138,000.00 |
| Revenue This Year | $4.43 | $33.62 |
| Revenue Next Year | $4.23 | $17.65 |
| P/E Ratio | $32.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.16 | $63.23 |
| 52 Week High | $53.89 | $130.00 |
Technical Indicators
Market Signals| Indicator | ST | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 35.31 |
| Support Level | $40.44 | $75.80 |
| Resistance Level | $43.84 | $104.56 |
| Average True Range (ATR) | 1.02 | 4.12 |
| MACD | 0.08 | 0.17 |
| Stochastic Oscillator | 54.24 | 24.65 |
Price Performance
Historical ComparisonAbout ST Sensata Technologies Holding plc
Sensata Technologies is a global supplier of sensors and electrical protection for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. It also sells electrical protection products, like contactors and relays. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.